Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Candin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nielsen Biosciences Enrolls First Patient in Phase 3 Trial of CANDIN for Common Warts
Details : Candin is a USFDA approved candida albicans skin test antigen for cellular immunity. It is now being evaluated for the treatment of common warts (Verruca vulgaris).
Product Name : Candin
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 03, 2024
Lead Product(s) : Candin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable